{"success":true,"data":{"pressRelease":{"id":"89821","rtpr_id":"nACSZZxC7a","ticker":"RVV","exchange":"","all_tickers":["RVV"],"title":"Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement","author":"ACCESSWIRE","published_at":"2026-07-15T22:40:00.943Z","article_body":"NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED\nSTATES\n\nTORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / July 15,\n2026 / Revive Therapeutics Ltd. (\"Revive\" or the \"Company\")\n(OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on\ninfectious diseases and medical countermeasures, announces that it has closed\nthe first tranche of its previously announced non-brokered private placement\nfor gross proceeds of $246,920 (the \"Private Placement\").\n\nThe Private Placement consisted of the issuance and sale of 7,716,250 units of\nthe Company (\"Units\"), at a price of $0.032 per Unit. Each Unit issued\npursuant to the Private Placement consists of one common share of the Company\n(a \"Common Share\") and one Common Share purchase warrant (a \"Warrant\"). Each\nWarrant will entitle the holder to acquire one Common Share at an exercise\nprice of $0.05 for a period of 36 months following the closing date of the\nPrivate Placement.\n\nThe Company intends to use the gross proceeds from the Private Placement\nprimarily for working capital purposes.\n\nIn connection with the first tranche closing, the Company has also paid\ncertain finders an aggregate of $17,433.60 and issued an aggregate of 537,300\nbroker warrants to purchase Common Shares (the \"Broker Warrants\"). Each Broker\nWarrant will entitle the holder to purchase one Common Share at an exercise\nprice equal to $0.05 for a period of 36 months following the closing of the\nPrivate Placement.\n\nThe Company will provide an update on any further closings under the Private\nPlacement.\n\nAll of the securities will be subject to a hold period of four months and one\nday from the date of issuance.\n\nAbout Revive Therapeutics Ltd.\n\nRevive Therapeutics is a life sciences company focused on the research and\ndevelopment of therapeutics for infectious diseases and medical\ncountermeasures. Revive prioritizes its drug-development efforts to take\nadvantage of regulatory incentives that may be available for important unmet\nmedical needs. The Company is currently exploring the use of bucillamine for\ninfectious diseases, nerve agent exposure and long COVID, among other\npotential applications. For more information, visit www.ReviveThera.com.\n\nFor more information, please contact:\n\nMichael Frank\nChief Executive Officer\nRevive Therapeutics Ltd.\nTel: 1 888 901 0036\nEmail: mfrank@revivethera.com\nWebsite: www.revivethera.com\n\nNeither the CSE nor its Regulation Services Provider has reviewed or accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Statement\n\nThis press release contains 'forward-looking information' within the meaning\nof applicable Canadian securities legislation. These statements relate to\nfuture events or future performance. The use of any of the words \"may\",\n\"could\", \"intend\", \"expect\", \"believe\", \"will\", \"projected\", \"estimated\" and\nsimilar expressions and statements relating to matters that are not historical\nfacts are intended to identify forward-looking information and are based on\nRevive's current belief or assumptions as to the outcome and timing of such\nfuture events. Forward looking information in this press release includes, but\nare not limited to: statements with respect to the use of proceeds and updates\nof any future closings under the Private Placement. Forward-looking\ninformation is based on reasonable assumptions that have been made by Revive\nat the date of the information and is subject to known and unknown risks,\nuncertainties, and other factors that may cause actual results or events to\ndiffer materially from those anticipated in the forward-looking information.\nGiven these risks, uncertainties and assumptions, you should not unduly rely\non these forward-looking statements. The forward-looking information contained\nin this press release is made as of the date hereof, and Revive is not\nobligated to update or revise any forward-looking information, whether as a\nresult of new information, future events or otherwise, except as required by\napplicable securities laws. The foregoing statements expressly qualify any\nforward-looking information contained herein. Reference is made to the risk\nfactors disclosed under the heading \"Risk Factors\" in the Company's\nmanagement's discussion and analysis for the three and nine months ended March\n31, 2026 , dated May 29, 2026, which is available on the Company's profile at\nwww.sedarplus.ca.\n\nSOURCE: Revive Therapeutics Ltd.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-announces-closing-of-first-tranche-of-non-brokere-1191730)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSZZxC7a","title":"Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement","author":"ACCESSWIRE","ticker":"RVV","created":"2026-07-15T22:40:00.943Z","tickers":["RVV"],"exchange":"","article_body":"NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED\nSTATES\n\nTORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / July 15,\n2026 / Revive Therapeutics Ltd. (\"Revive\" or the \"Company\")\n(OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on\ninfectious diseases and medical countermeasures, announces that it has closed\nthe first tranche of its previously announced non-brokered private placement\nfor gross proceeds of $246,920 (the \"Private Placement\").\n\nThe Private Placement consisted of the issuance and sale of 7,716,250 units of\nthe Company (\"Units\"), at a price of $0.032 per Unit. Each Unit issued\npursuant to the Private Placement consists of one common share of the Company\n(a \"Common Share\") and one Common Share purchase warrant (a \"Warrant\"). Each\nWarrant will entitle the holder to acquire one Common Share at an exercise\nprice of $0.05 for a period of 36 months following the closing date of the\nPrivate Placement.\n\nThe Company intends to use the gross proceeds from the Private Placement\nprimarily for working capital purposes.\n\nIn connection with the first tranche closing, the Company has also paid\ncertain finders an aggregate of $17,433.60 and issued an aggregate of 537,300\nbroker warrants to purchase Common Shares (the \"Broker Warrants\"). Each Broker\nWarrant will entitle the holder to purchase one Common Share at an exercise\nprice equal to $0.05 for a period of 36 months following the closing of the\nPrivate Placement.\n\nThe Company will provide an update on any further closings under the Private\nPlacement.\n\nAll of the securities will be subject to a hold period of four months and one\nday from the date of issuance.\n\nAbout Revive Therapeutics Ltd.\n\nRevive Therapeutics is a life sciences company focused on the research and\ndevelopment of therapeutics for infectious diseases and medical\ncountermeasures. Revive prioritizes its drug-development efforts to take\nadvantage of regulatory incentives that may be available for important unmet\nmedical needs. The Company is currently exploring the use of bucillamine for\ninfectious diseases, nerve agent exposure and long COVID, among other\npotential applications. For more information, visit www.ReviveThera.com.\n\nFor more information, please contact:\n\nMichael Frank\nChief Executive Officer\nRevive Therapeutics Ltd.\nTel: 1 888 901 0036\nEmail: mfrank@revivethera.com\nWebsite: www.revivethera.com\n\nNeither the CSE nor its Regulation Services Provider has reviewed or accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Statement\n\nThis press release contains 'forward-looking information' within the meaning\nof applicable Canadian securities legislation. These statements relate to\nfuture events or future performance. The use of any of the words \"may\",\n\"could\", \"intend\", \"expect\", \"believe\", \"will\", \"projected\", \"estimated\" and\nsimilar expressions and statements relating to matters that are not historical\nfacts are intended to identify forward-looking information and are based on\nRevive's current belief or assumptions as to the outcome and timing of such\nfuture events. Forward looking information in this press release includes, but\nare not limited to: statements with respect to the use of proceeds and updates\nof any future closings under the Private Placement. Forward-looking\ninformation is based on reasonable assumptions that have been made by Revive\nat the date of the information and is subject to known and unknown risks,\nuncertainties, and other factors that may cause actual results or events to\ndiffer materially from those anticipated in the forward-looking information.\nGiven these risks, uncertainties and assumptions, you should not unduly rely\non these forward-looking statements. The forward-looking information contained\nin this press release is made as of the date hereof, and Revive is not\nobligated to update or revise any forward-looking information, whether as a\nresult of new information, future events or otherwise, except as required by\napplicable securities laws. The foregoing statements expressly qualify any\nforward-looking information contained herein. Reference is made to the risk\nfactors disclosed under the heading \"Risk Factors\" in the Company's\nmanagement's discussion and analysis for the three and nine months ended March\n31, 2026 , dated May 29, 2026, which is available on the Company's profile at\nwww.sedarplus.ca.\n\nSOURCE: Revive Therapeutics Ltd.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-announces-closing-of-first-tranche-of-non-brokere-1191730)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-15T22:40:00.981383829Z","server_sent_at_ms":1784155200981},"received_at":"2026-07-15T22:40:01.047Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-announces-closing-of-first-tranche-of-non-brokere-1191730"},"analysis":{"id":"78873","press_release_id":"89821","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Revive Therapeutics closed the first tranche of a non-brokered private placement, raising gross proceeds of $246,920.\n\nThe company issued 7.7 million units at a price of $0.032 per unit, with each unit consisting of one common share and one warrant exercisable at $0.05 over 36 months.\n\nNet proceeds are intended for working capital purposes, and all issued securities are subject to a four-month hold period.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine micro-cap financing closed."},"keyFigures":{"dealValueUsd":246920,"offeringPrice":0.032,"sharesOffered":7716250,"customDimensions":{"broker_warrants":537300,"warrants_per_unit":1,"warrant_term_months":36,"warrant_exercise_price":0.05}},"quotedText":"","namedEntities":{"people":[{"name":"Michael Frank","role":"Chief Executive Officer"}],"products":["bucillamine"],"companies":[{"name":"Revive Therapeutics Ltd.","ticker":"RVV"}],"dollarAmounts":[{"amount":"$246,920","context":"gross proceeds of first tranche"},{"amount":"$0.032","context":"price per Unit"},{"amount":"$0.05","context":"Warrant exercise price"},{"amount":"$17,433.60","context":"aggregate finders fee"}]},"materialImpact":{"score":1,"reasoning":"Small-dollar private placement ($247k gross) for working capital; routine financing event for a micro-cap with negligible market impact."},"tickerRelevance":{"others":[],"primary":"RVV"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":["dilution"],"importanceComponents":{"dealSize":"<$250k","tickerTier":"micro-cap","eventGravity":"routine-financing"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":1,"narrative":"Revive Therapeutics closed the first tranche of a non-brokered private placement, raising gross proceeds of $246,920.\n\nThe company issued 7.7 million units at a price of $0.032 per unit, with each unit consisting of one common share and one warrant exercisable at $0.05 over 36 months.\n\nNet proceeds are intended for working capital purposes, and all issued securities are subject to a four-month hold period.","key_figures":{"dealValueUsd":246920,"offeringPrice":0.032,"sharesOffered":7716250,"customDimensions":{"broker_warrants":537300,"warrants_per_unit":1,"warrant_term_months":36,"warrant_exercise_price":0.05}},"named_entities":{"people":[{"name":"Michael Frank","role":"Chief Executive Officer"}],"products":["bucillamine"],"companies":[{"name":"Revive Therapeutics Ltd.","ticker":"RVV"}],"dollarAmounts":[{"amount":"$246,920","context":"gross proceeds of first tranche"},{"amount":"$0.032","context":"price per Unit"},{"amount":"$0.05","context":"Warrant exercise price"},{"amount":"$17,433.60","context":"aggregate finders fee"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T23:01:31.552Z","global_importance":5,"audience_relevance":5,"importance_components":{"dealSize":"<$250k","tickerTier":"micro-cap","eventGravity":"routine-financing"}},"durationMs":208364,"modelName":"glm-4.7"}}